Anti-Rheumatic Drugs - EU-27

EU-27

The Anti-Rheumatic Drugs market in the EU-27 is forecasted to achieve a revenue of US$3.58bn by the year 2024.
Furthermore, it is expected to exhibit a Compound Annual Growth Rate (CAGR) of 0.44% between 2024 and 2029, leading to a market volume of US$3.66bn by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue of US$34,700.00m in 2024.
In Germany, the market for anti-rheumatic drugs is characterized by a strong focus on research and development, with a high demand for innovative treatments.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in EU-27 has seen a steady growth in recent years.

Customer preferences: The demand for Anti-Rheumatic Drugs in EU-27 has been driven by the increasing prevalence of rheumatoid arthritis, osteoarthritis, and other rheumatic diseases. The aging population has also contributed to the growth of the market, as these diseases are more common in older individuals. Additionally, the rising awareness about the benefits of early diagnosis and treatment of rheumatic diseases has led to an increase in demand for Anti-Rheumatic Drugs.

Trends in the market: The Anti-Rheumatic Drugs market in EU-27 is characterized by intense competition among the major players. There has been a trend towards the development of biologic drugs, which are more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs). Biologic drugs are more expensive than DMARDs, but their superior efficacy has led to an increase in their usage. There has also been a trend towards the development of biosimilars, which are less expensive versions of biologic drugs.

Local special circumstances: Germany is the largest market for Anti-Rheumatic Drugs in EU-27, followed by France and the United Kingdom. The market in Germany is driven by the high prevalence of rheumatoid arthritis in the country, as well as the availability of innovative drugs. The market in France is characterized by the high usage of biologic drugs, while the market in the United Kingdom is driven by the availability of biosimilars.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in EU-27 is supported by favorable macroeconomic factors such as increasing healthcare expenditure and the availability of healthcare insurance. The aging population is also contributing to the growth of the market, as the prevalence of rheumatic diseases is higher in older individuals. However, the market is also facing challenges such as increasing pricing pressure and the entry of biosimilars, which are expected to impact the revenues of the major players in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.